Posted by Michael Wonder on 04 Aug 2021
Cerus Corporation announces CMS has granted new technology add-on payment for INTERCEPT fibrinogen complex
3 August 2021 - New technology add-on payment provides incremental reimbursement under CMS’ Inpatient Prospective Payment System for INTERCEPT Fibrinogen Complex.
Cerus Corporation today announced that the U.S. CMS has granted a new technology add-on payment for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System.
The new technology add-on payment was granted under CMS’ alternative new technology add-on payment pathway, which recognises the transformative nature of products granted breakthrough device designation by the U.S. FDA.
